Dr. Anette-Gabriele Ziegler was selected as the 2025 Hamm Prize laureate in recognition of her lifetime achievement in Type 1 Diabetes (T1D), including her contribution to understanding the pathogenesis and mechanisms leading to T1D, as well as its prevention.
She began her career as a physician-scientist at Klinikum Schwabing in Munich in 1984, where she established her first independent laboratory. She then received postdoctoral training at the Joslin Diabetes Center and Harvard Medical School, and went on to specialize in internal medicine, diabetes, and endocrinology. Dr. Ziegler became the founding Director and Head of the Institute of Diabetes Research at Helmholtz Munich and the German Research Center for Environmental Health in Munich, Germany. She was also appointed to a full professorship at the Technical University of Munich. In collaboration with Helmholtz Munich and the Technical University of Munich, she established an internationally renowned Study Center for Childhood Diabetes – Early Care and Prevention – dedicated to investigating the natural history of type 1 diabetes and translating her findings into novel treatment strategies tested in clinical trials aimed at preventing the disease.
Her extensive research program has been pivotal in developing the T1D staging classification system, which defines distinct stages of the disease before and after the onset of symptoms. She identified insulin as the key autoantigen in childhood T1D, invented polygenic risk scores for the identification of newborns at risk for T1D. She also pioneered several important clinical trials in type 1 diabetes, including her rigorous research on high-dose oral insulin immunotherapy, which has been pivotal in laying the foundation for the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD), where she has served as Speaker for the past ten years.
Her contributions to the field have been recognized with numerous international research prizes and awards, including the prestigious Mary Taylor Moore Excellence Award of the Juvenile Diabetes Research Foundation, the EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, and the Paul Langerhans Medal, the highest honor awarded by the German Diabetes Association.
Sir Stephen O’Rahilly, M.D., FRS, FMedSci, is a Professor and Head of the Clinical Biochemistry and Medicine department at the University of Cambridge. O’Rahilly also co-directs the Wellcome-MRC Institute of Metabolic Science (IMS), one of the world’s largest institutes for metabolic research at the University of Cambridge.
Dr. O’Rahilly is a graduate of the University College of Dublin and the National University of Ireland. Before his appointment to the University of Cambridge, O’Rahilly held clinical and research fellow positions at the University of Oxford and Harvard University.
O’Rahilly was selected as the 2023 Hamm Prize laureate for his research that linked a specific mechanism to the development of obesity. Obesity is considered the biggest risk factor for Type 2 diabetes and O’Rahilly’s rigorous clinical research defined very specific molecular mechanisms and genes that are responsible for the condition of obesity.
In addition to the Hamm Prize, his findings have been recognized internationally with many awards and prizes. In 2013 he was knighted by Queen Elizabeth for services to medical research, specifically, his work in diabetes research.
Watch the 2023 Hamm Prize Laureate Video
Andrew T. Hattersley, CBE, FMedSci, FRS, is a Professor of Molecular Medicine at the University of Exeter Medical School, U.K. Hattersley’s career began as a research student working at Oxford. His early work at Exeter included establishing a lab that now leads the world in the study of MODY and neonatal diabetes research and diagnosis. Here, a major breakthrough occurred with genome-wide analysis; the collaborative approach paved the way to the discovery of new susceptibility polymorphism, a predisposition for Type 2 diabetes.
For nearly three decades, Hattersley has continued to make fundamental discoveries in diabetes research in both basic and clinical sciences, and his prolific work includes more than 600 peer-reviewed publications. Directing his research into the area of monogenic beta-cell diabetes, Hattersley has pushed beyond gene discovery to explore development and function of the human beta-cell, providing the clinical research that has become the basis of clinical care worldwide. One major advance has been the incorporation of beta-cell science into patient treatment. Recent work has revealed new insights into the beta-cell potassium channel.
Hattersley said the work of his research team in rare patients with genetic diabetes has shown that defining the cause of a person's diabetes can lead to dramatic improvements in treatment, including thousands of patients coming off insulin therapy.
Watch the 2021 Hamm Prize Laureate Video
Daniel J. Drucker, M.D., received his medical degree from the University of Toronto in 1980, and is currently Professor of Medicine at the University of Toronto. He holds a Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. His laboratory is based in the Lunenfeld Tanenbaum Research Institute at Mt. Sinai Hospital and studies the molecular biology and physiology of the glucagon-like peptides. Dr. Drucker's scientific studies identified multiple novel mechanisms of gut hormone action, resulting in 33 issued US patents, and enabling development of new drug classes for diabetes, obesity and intestinal failure. His discoveries have been recognized by numerous learned societies including the Banting Award from the ADA, the Claude Bernard Award from the EASD, the Manpei Suzuki International Prize for Diabetes Research, the Rolf Luft Award from the Karolinska Institute, the Harrington-ASCI Prize for Innovation in Medicine, and election to Fellowship, the Royal Society, London.
Watch the 2019 Hamm Prize Laureate Video
Ralph A. DeFronzo, MD, is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Deputy Director of the Texas Diabetes Institute, San Antonio, Texas. Dr. DeFronzo is a graduate of Yale University (BS) and Harvard Medical School (MD) and did his training in Internal Medicine at the Johns Hopkins Hospital. He completed fellowships in Endocrinology at the National Institutes of Health and Baltimore City Hospitals and in Nephrology at the Hospital of the University of Pennsylvania. Subsequently, he joined the faculty at the Yale University School of Medicine (1975-88) as an Assistant/Associate Professor. From 1988 to present Dr. DeFronzo has been Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center at San Antonio. He also serves as the Deputy Director of the Texas Diabetes Institute.
His major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus and the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders known collectively as the Insulin Resistance Syndrome. Using the euglycemic insulin clamp technique in combination with radioisotope turnover methodology, limb catheterization, indirect calorimetry, and muscle biopsy, he has helped to define the biochemical and molecular disturbances responsible for insulin resistance in type 2 diabetes mellitus.
For his work in this area, Dr. DeFronzo received the prestigious Lilly Award by the American Diabetes Association, the Banting Lectureship by the Canadian Diabetes Association, the Novartis Award for outstanding clinical investigation world wide, the Albert Renold Award, the Banting Award, and the Claude Bernard Award from the EASD. These represent the highest scientific achievement awards given by the American and European Diabetes Associations, respectively.
While in Oklahoma City to receive the Hamm Prize, Dr. DeFronzo delivered the Hamm Prize Lecture in Diabetes Research.
Watch the 2017 Hamm Prize Laureate Video
C. Ronald Kahn is a world recognized expert in diabetes and obesity research, as well as a preeminent investigator in the area of insulin signal transduction and mechanisms of altered signaling in diabetes and metabolic disease. Dr. Kahn is Senior Investigator, Head of the Section on Integrative Physiology and Metabolism at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School. Dr. Kahn served as Research Director of the Joslin Diabetes Center from 1981 to 2000, and served as President of Joslin from 2001 to 2007. He is currently the Center’s Chief Academic Officer.
Dr. Kahn has received more than 70 awards and honors, including the highest honors of the American Diabetes Association, U.S. and British Endocrine Societies, Juvenile Diabetes Research Foundation, European Association for the Study of Diabetes and the American Association of Clinical Endocrinologists, and election to the National Academy of Science and Institute of Medicine. He has authored more than 600 original publications and 200 reviews and chapters.
Dr. Kahn holds undergraduate and medical degrees from the University of Louisville. He also holds an honorary Master of Science from Harvard University, honorary Doctor of Science degrees from the University of Paris, University of Louisville, University of Geneva and Washington University in St. Louis, an honorary Doctor of Medicine from the University of Copenhagen and is an honorary Professor and Director of the Diabetes Center at Peking University School of Medicine.
Watch the 2015 Hamm Prize Laureate Video
Dr. Peter H. Bennett is widely-regarded as an international leader in diabetes research. He was the first to initiate a major longitudinal study of type 2 diabetes and its complications which led to the international standardization of diagnostic criteria by the World Health Organization. His Pima Study, Da Qing study, and Finnish study serve as the foundation for diabetes prevention programs around the world including the Centers for Disease Control Diabetes Prevention Program. Dr. Bennett remains a mentor to thousands of young diabetes researchers trained by his international epidemiology seminars.
Dr. Bennett's unparalleled achievements in the field of diabetes research is the genesis for much of what we know about diabetes, its mechanisms, its complications, and its eventual cure.
Read Dr. Bennett's full biography.
Watch the 2013 Hamm Prize Laureate Video
Spring 2025 Newsletter The Spring issue highlights: Matthew Pothoff is Named New Deputy Director Research News Milk as Medicine: Study Shows Breast ...
Fall 2024 Newsletter (pdf) The Fall issue highlights: Dr. Friedman Meets with the Director of the National Institutes of Health, Dr. Monica ...
The Harold Hamm Diabetes Center (HHDC) at the University of Oklahoma Health Sciences will gain a new deputy director, Matthew Potthoff, Ph.D., ...
